Welcome to our dedicated page for Kkr & Co news (Ticker: KKR), a resource for investors and traders seeking the latest updates and insights on Kkr & Co stock.
KKR & Co Inc (KKR) is a leading global alternative asset manager with a 45+ year track record in private equity, credit, and infrastructure investments. This page provides investors and financial professionals with timely access to official press releases, earnings reports, and strategic updates directly from KKR.
Key resources include: Quarterly earnings announcements, merger & acquisition disclosures, leadership updates, and partnership developments. Our curated feed ensures you stay informed about KKR's global initiatives across private markets, real estate, and insurance solutions through Global Atlantic Financial Group.
Bookmark this page for verified updates on KKR's investment activities, ESG commitments, and capital allocation strategies. All content is sourced from official company communications to ensure accuracy and compliance with financial disclosure standards.
KKR (NYSE:KKR) has announced the acquisition of ProTen Pty Limited, one of Australia's largest agricultural infrastructure businesses, from Aware Super. ProTen is a significant player in Australia's poultry supply chain, managing over 700 poultry sheds across more than 60 farms nationwide.
The acquisition represents KKR's strategic entry into the agricultural infrastructure space, with the investment being made through its Asia Pacific Infrastructure Investors II Fund. ProTen, established in 2001, has been under Aware Super's ownership since 2018, during which time it experienced significant growth including a four-fold expansion of its property portfolio.
The transaction, which is expected to close later in 2025 subject to regulatory approvals, adds to KKR's growing infrastructure portfolio in the Australia & New Zealand region, which includes investments in Zenith Energy, Queensland Airports Limited, Spark Infrastructure, and Ritchies Transport. KKR's Asia Pacific infrastructure platform currently manages approximately US$13 billion in assets.
KKR (NYSE:KKR) has announced its second residential investment in Stockholm through a forward funding agreement with Swedish developer Reliwe for a new multifamily development in Täby. The project consists of three residential assets totaling 325 units with approximately 15,300 square meters of lettable area, scheduled for completion between 2026 and 2028.
Located 14 kilometers from Stockholm's city center, the development offers excellent public transport connectivity and proximity to Täby Centrum shopping center. This investment follows KKR's February 2025 investment in Haninge, bringing their Stockholm residential portfolio to approximately 700 units under development. The project will be managed in partnership with local operator Cavendo.
KKR has committed over SEK 6 billion to real estate investments in the Nordics, focusing on residential and logistics assets. The investment is being made through KKR's European Real Estate strategy.
KKR (NYSE:KKR) has announced the launch of Ascend Asia Financial Services Group, a new financial advisory platform in Singapore. The platform's first strategic move includes the acquisition of finexis advisory and its affiliates through KKR-managed funds.
The platform will be led by CEO Tomas Urbanec, former CEO of Prudential Singapore, alongside a seasoned leadership team including Chief Risk & Compliance Officer Tan Siew Yen and General Counsel Leonard Ong. Patrick Teow, former CEO of AIA Singapore, will serve as Senior Advisor.
Ascend Asia aims to empower member firms by providing strategic expertise, industry knowledge, and resources to enhance their capabilities. finexis, as the inaugural member, will continue to operate under its own brand with no changes to existing client relationships. The transaction, which has received in-principle approval from the Monetary Authority of Singapore, is expected to close in Q3 2025.
KKR (NYSE:KKR) has announced an agreement to sell its controlling stake in J.B. Chemicals & Pharmaceuticals (JB Pharma) to Torrent Pharmaceuticals in a significant two-phase transaction valued at INR 25,689 crores (on fully diluted basis).
The transaction structure includes: 1) Acquisition of 46.39% equity stake through a Share Purchase Agreement at INR 11,917 crores (INR 1,600 per share), followed by a mandatory open offer for up to 26% additional shares at INR 1,639.18 per share. 2) Merger between Torrent and JB Pharma where shareholders will receive 51 Torrent shares for every 100 JB Pharma shares.
The strategic acquisition strengthens Torrent's presence in the Indian pharmaceutical market, particularly in chronic segments, while providing entry into new areas like ophthalmology and CDMO capabilities. The deal requires approvals from various regulatory bodies including SEBI, Stock Exchanges, CCI, and NCLT.